Verisante Technology, Inc. has amended its exclusive agreement with bo pharma BV to distribute skin cancer diagnostic Verisante Aura in Sweden, Norway, Denmark, Finland and Iceland, in addition to Belgium, the Netherlands and Luxemburg. Aura received Conformite Europeenne (CE) Mark approval, which is recognized by all 27 Member States of the EU, including Sweden, Denmark and Finland, as well as Norway and Iceland.
"Bo pharma is committed to expanding its distribution facilities to service this region," said Thomas Braun, president and chief executive officer of Verisante. "With this foundation and bo pharma’s experience and expertise in distributing the world’s top brands in dermatological and skin care devices; this provides us with an excellent opportunity to expand our partnership into this important region. Bo pharma has the resources to both distribute Aura, and provide support, technical training and servicing in the Nordic countries."
"Aura is a game-changing device in the field of skin cancer diagnosis," said Dr. Henk-Peter Oonk, chief executive officer of bo pharma. "We anticipate significant demand of this new technology in Benelux and welcome the opportunity to widen this adoption into the Nordic countries, where bo pharma has rapid expansion plans."